Aull & Monroe Investment Management Corp continued to hold its stake in Becton, Dickinson and Company (NYSE:BDX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,600 shares of the medical instruments supplier’s stock at the end of the second quarter. Aull & Monroe Investment Management Corp’s holdings in Becton, Dickinson and were worth $312,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Almanack Investment Partners LLC. bought a new position in shares of Becton, Dickinson and in the 1st quarter valued at about $105,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its position in shares of Becton, Dickinson and by 55.8% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock valued at $131,000 after acquiring an additional 240 shares during the period. Parkside Financial Bank & Trust grew its position in shares of Becton, Dickinson and by 8.1% in the 2nd quarter. Parkside Financial Bank & Trust now owns 684 shares of the medical instruments supplier’s stock valued at $133,000 after acquiring an additional 51 shares during the period. Harfst & Associates Inc. grew its position in shares of Becton, Dickinson and by 46.4% in the 2nd quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock valued at $135,000 after acquiring an additional 221 shares during the period. Finally, Financial Architects Inc grew its position in shares of Becton, Dickinson and by 8.0% in the 2nd quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock valued at $142,000 after acquiring an additional 54 shares during the period. 87.12% of the stock is owned by institutional investors.

In other Becton, Dickinson and news, insider Ellen R. Strahlman sold 9,283 shares of the stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $198.21, for a total transaction of $1,839,983.43. Following the completion of the transaction, the insider now owns 26,638 shares in the company, valued at $5,279,917.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of the stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the transaction, the insider now owns 12,861 shares of the company’s stock, valued at approximately $2,538,890.01. The disclosure for this sale can be found here. Insiders have sold 75,904 shares of company stock valued at $15,242,688 in the last quarter. Company insiders own 1.40% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Becton, Dickinson and Company (BDX) Holdings Maintained by Aull & Monroe Investment Management Corp” was reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/10/21/becton-dickinson-and-company-bdx-holdings-maintained-by-aull-monroe-investment-management-corp.html.

BDX has been the subject of a number of analyst reports. Raymond James Financial, Inc. raised shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and decreased their price objective for the company from $210.00 to $180.00 in a research report on Friday, June 30th. Cowen and Company restated an “outperform” rating and set a $230.00 target price (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Monday, July 10th. BidaskClub upgraded shares of Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 11th. Zacks Investment Research upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 target price for the company in a research note on Monday, July 17th. Finally, Bank of America Corporation restated a “buy” rating and set a $225.00 target price (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. Five analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Becton, Dickinson and has a consensus rating of “Buy” and a consensus price target of $200.93.

Shares of Becton, Dickinson and Company (NYSE BDX) opened at 211.83 on Friday. The firm has a 50-day moving average of $198.29 and a 200 day moving average of $193.82. The firm has a market cap of $48.20 billion, a PE ratio of 61.35 and a beta of 1.05. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $212.54.

Becton, Dickinson and (NYSE:BDX) last issued its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, topping analysts’ consensus estimates of $2.44 by $0.02. The firm had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The company’s quarterly revenue was down 5.1% on a year-over-year basis. During the same quarter last year, the business earned $2.35 earnings per share. Equities research analysts predict that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, September 29th. Shareholders of record on Friday, September 8th were given a dividend of $0.73 per share. The ex-dividend date of this dividend was Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a yield of 1.38%. Becton, Dickinson and’s dividend payout ratio is presently 83.43%.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.